Close Menu

GeneCentric Diagnostics

GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.

The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.

The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.

The partners will evaluate patients' responses to immunotherapeutic drugs, including PD-1 and PDL-1 inhibitors, based on bladder cancer subtypes.

The University of North Carolina at Chapel Hill's technology is based on set of patient-cell derived gene signatures for classifying four pancreatic subtypes.

The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.

BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.